AG
CRBU icon

Artal Group’s Caribou Biosciences CRBU Stock Holding History

Artal Group’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-105,347
Closed -$173K – 21
2024
Q2 		$173K Hold
105,347
– – ﹤0.01% 109
2024
Q1 		$541K Hold
105,347
– – 0.01% 104
2023
Q4 		$604K Hold
105,347
– – 0.02% 79
2023
Q3 		$504K Hold
105,347
– – 0.02% 85
2023
Q2 		$448K Hold
105,347
– – 0.01% 103
2023
Q1 		$559K Hold
105,347
– – 0.03% 101
2022
Q4 		$662K Hold
105,347
– – 0.04% 114
2022
Q3 		$1.11M Hold
105,347
– – 0.05% 111
2022
Q2 		$572K Hold
105,347
– – 0.03% 121
2022
Q1 		$967K Sell
105,347
-300,000
-74% -$3.16M 0.04% 124
2021
Q4 		$6.12M Hold
405,347
– – 0.17% 93
2021
Q3 		$9.68M Buy
+405,347
New +$9.91M 0.22% 82

Other funds holding CRBU

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
EWM
Elmwood Wealth Management Berkeley, California $400M AUM 17.81% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Artal Group's CRBU Position: Q3 2024 in Review

Artal Group sold out of Caribou Biosciences (CRBU) in Q3 2024, closing a stake of 105,347 shares — an estimated $173K sold.

Artal Group first reported a position in CRBU in Q3 2021 and held it in 12 quarters. The position peaked at $9.68M in Q3 2021. 129 funds tracked by Wall St. Rank hold CRBU as of Q3 2024.

  • Artal Group reported no remaining Caribou Biosciences position as of Q3 2024 after selling out during the quarter.
  • Artal Group sold 105,347 Caribou Biosciences shares in Q3 2024, an estimated $173K.
  • Artal Group first reported a position in Caribou Biosciences in Q3 2021 and held it in 12 quarters.
  • Artal Group's Caribou Biosciences position peaked at $9.68M in Q3 2021.
  • 129 funds tracked by Wall St. Rank held Caribou Biosciences as of Q3 2024.

Based on Artal Group's 13F filing for Q3 2024, filed 13 Nov 2024.